Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

http://www.wikidata.org/entity/Q33982372

about

Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants Applications of CYP450 testing in the clinical setting Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs Association between Tumor Necrosis Factor-α (-238G/A and -308G/A) Gene Polymorphisms and Risk of Ischemic Stroke: A Meta-Analysis Impact of New Genomic Technologies on Understanding Adverse Drug Reactions The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients Genetic variants and the risk of gestational diabetes mellitus: a systematic review Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications.CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.Personalizing health care: feasibility and future implications.Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.Addressing phenoconversion: the Achilles' heel of personalized medicine.Clopidogrel: a case for indication-specific pharmacogenetics.Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention.Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.Personalized medicine: is it a pharmacogenetic mirage?Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.Pharmacogenomic testing and antithrombotic therapy: ready for prime time?Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association.Pharmacogenetics and cardiovascular disease--implications for personalized medicine Regulatory polymorphisms in CYP2C19 affecting hepatic expression Pharmacogenetic testing: Current Evidence of Clinical Utility.The CYP2C19*17 variant is not independently associated with clopidogrel response.Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?Cytochrome P450 variations in different ethnic populations.Genetic and non-genetic factors affecting the response to clopidogrel therapy.Blood biomarkers in stroke: research and clinical practice.Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.Advances in the monitoring of anti-P2Y12 therapy.Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention.Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.Pharmacogenomics of anti-platelet and anti-coagulation therapy.Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists.Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-analysis.

P2860

Q24273409-6249A889-9682-4890-B570-7BB40129675D Q24621760-E8DE08D6-8355-45F1-93BA-489B3D2ED1F3 Q24633087-4691E4E0-F4DE-4F75-A06C-225967FE2CB5 Q26747894-13DDDB81-D23F-4323-B0D0-0D1F9752464B Q26787099-1EC03F76-7555-4424-8403-5CF5CE63E3FF Q26801867-BBA71F1E-DCAD-4CD8-B9F1-E6618235729F Q26822796-7E579278-C5CB-4C61-AA61-48816ED0E6A3 Q26996594-7C3B2D88-5B5E-4656-AADA-7412CA64A0AD Q28291029-C211B174-7846-48B8-8451-0B02B5689F4B Q33837665-A58AC714-82FB-4EB8-8CB6-6E0F88028CF1 Q34166239-5ABDA854-FF7E-4CFB-9933-E65C772A3364 Q34307589-7614B750-8357-4B28-B8A1-206B714F46C8 Q34532327-FA340C1F-A9E2-4A92-AB7E-355C93B8CF11 Q34649009-12FBD09C-82E1-4158-BF2A-AD12AD5BBA98 Q34938911-553B771B-A734-43DF-966B-47A954DD7873 Q34981428-ADC35DD8-F06F-49DE-8D0D-4AFA8A995599 Q35023701-F416E9AD-6BFE-4A76-87A5-24B46A68B9CB Q36055186-D08D5258-800F-4960-B87B-20EDCC6C024A Q36216896-EA274389-B162-4877-8D32-3681A2D5059A Q36307008-2C8F30C4-D1C8-4241-9409-3F8B4456A0EF Q36336007-05F246C5-582F-4285-8DB6-206203294940 Q36391044-6A828245-D28C-4128-BBEE-DC4AFDF55145 Q36919495-6267EE2B-B0D9-47A4-98F5-9C078F8B5275 Q36953147-BFF4AB12-3D1D-4E2B-8A2D-F4645DA209B4 Q36974672-D32590EB-6078-4DE2-9B8F-95E25529D878 Q37127419-89D44AC8-0634-4CD3-AFE6-464C945D4A50 Q37151528-9CA74B28-370D-466A-9C3D-19B1AFFE2B8B Q37171415-4FBD32E1-DD71-4AAB-8785-7596BABE5556 Q37973457-61243031-0929-4845-A9DE-127F012FFABC Q37979866-0B3936FF-FC1C-4E35-A0EB-56FF1DFE7DD4 Q37991382-BBF045F6-E7A4-480F-84BD-6742C84D2B5E Q37998544-2C789C7B-4F3E-4EBE-AA76-6B3D1A74CE19 Q38004103-4E801DDF-68A9-4A0D-A6B6-4CC9A47A6200 Q38037121-0D33FDA1-DCFC-4FD2-89A0-F8B1EA9E7D83 Q38056525-B6CFAE38-9606-406E-8C32-658EAB869599 Q38106616-A807CD27-01B8-4695-A67C-39496A1B3B56 Q38116753-B6100416-BBB9-4B56-A09F-BD51A76187B9 Q38117748-7AF0D153-32A0-4897-B439-D452110CDD2B Q38132252-CAB4B559-F2C7-4F5C-94D9-44B03C440CCD Q38135780-DD44BF9E-DEBE-43AD-AD1F-E2888A1605B6

P2860

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

http://www.wikidata.org/entity/Q33982372

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Impact of CYP2C19 variant geno ...... atic review and meta-analysis.

@ast

Impact of CYP2C19 variant geno ...... atic review and meta-analysis.

@en

type

label

Impact of CYP2C19 variant geno ...... atic review and meta-analysis.

@ast

Impact of CYP2C19 variant geno ...... atic review and meta-analysis.

@en

prefLabel

Impact of CYP2C19 variant geno ...... atic review and meta-analysis.

@ast

Impact of CYP2C19 variant geno ...... atic review and meta-analysis.

@en

P1433

Q33982372-A249A594-D926-4C0E-B06B-9C5ECA163734

P1476

Q33982372-32A2C557-044F-47C0-BAA8-374825929849

P2093

Q33982372-22AEEC1A-7A1B-4296-9871-C815CA30E7D5

Q33982372-317320B3-4708-463B-9402-DF61F7E9D81A

Q33982372-48C61AE1-A697-45BB-AB69-E16D105C2EA6

Q33982372-55B270E5-193F-480B-B486-DEB2B1F04163

Q33982372-5DA1C7C4-D1A9-40E1-A737-953988529D3F

Q33982372-B3201A49-CAF7-4091-83F0-6160E511644E

P275

Q33982372-0D670984-16FF-498A-A129-35C410562BC9

P2860

Q33982372-00D568AF-7FD5-4A67-B379-9AF8239C4E16

Q33982372-01C8075B-61BD-4FEE-92E8-769D8EB780F2

Q33982372-03142A98-270C-4997-B5C8-772AD4D5DFDD

Q33982372-0490897E-4FD0-4D5D-9286-20B76DFD47E0

Q33982372-056E05B2-5647-4605-A824-2606DC66A58E

Q33982372-08DDDA8E-D4A5-4BE9-B39B-33941DE826F3

Q33982372-0AB198EA-F771-4B2D-9AC6-89D75E0E85FA

Q33982372-0C69915A-B7F6-4321-8775-5988FA297C20

Q33982372-0F1AFE7D-ECA1-4C5E-80CD-BC83B311164B

Q33982372-189E6702-D023-4677-8E3B-00A668713CD7

P304

Q33982372-61D9FCAD-DFBC-41A3-B518-31FA0F052FBD

P31

Q33982372-4D99DEBC-1467-4B47-92B2-7E8CC7DD4AED

Q33982372-509CCBCA-A7E9-46D3-8C9D-6E00ADAC5570

Q33982372-bc5bfdd4-c588-41bd-abe4-b917d760195d

P356

Q33982372-9C1A4954-F2C6-4CF8-9219-D7FA1DF28B77

P407

Q33982372-F151330D-08DB-412C-A4BB-AFD3303E6383

P478

Q33982372-C9ADFF7F-3463-41AE-BA84-EF182416074C

P577

Q33982372-945825FA-4AB3-41F3-B502-9339B63BAC55

P5875

Q33982372-A0A9CCA2-EC72-400C-B867-D5E4E21B9807

P698

Q33982372-B978D2FA-24F9-4561-8BDE-F6559429F357

P921

Q33982372-420878A2-AFD2-4352-9097-0832D8C09831

Q33982372-55D79EFE-A1DC-4139-9F51-0AC25B727CD2

Q33982372-71335214-9E89-4612-B270-87F324030B64

Q33982372-A31FF384-791C-43D7-919B-0D99B3FA8FCE

Q33982372-CAA0C178-725A-4DDA-898A-D8ACC46411FB

Q33982372-F50FBB53-42E8-4F63-8093-349E71D2F9C9

P932

Q33982372-899D3D88-2B26-47AA-9783-FAB0D06A9A45

P356

P1433

P1476

Impact of CYP2C19 variant geno ...... atic review and meta-analysis.

@en

P2093

Dirk Taubert

http://www.w3.org/2001/XMLSchema#string

Heleen J Bouman

http://www.w3.org/2001/XMLSchema#string

Jochem W van Werkum

http://www.w3.org/2001/XMLSchema#string

Jurriën M ten Berg

http://www.w3.org/2001/XMLSchema#string

Neville F Ford

http://www.w3.org/2001/XMLSchema#string

Tim Bauer

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

What is "quality of evidence" and why is it important to clinicians?

The Measurement of Observer Agreement for Categorical Data

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

Quantifying heterogeneity in a meta-analysis

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

Replication validity of genetic association studies

P304

d4588

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.D4588

http://www.w3.org/2001/XMLSchema#string

P407

P478

343

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51547332

http://www.w3.org/2001/XMLSchema#string

P698

21816733

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

genetic variation

P932

3191560

http://www.w3.org/2001/XMLSchema#string